Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2023 Booster in Adults Previously Vaccinated with Inactivated COVID-19 Vaccine
NCT05926440Phase 3Withdrawn
- Sponsor
- Clover Biopharmaceuticals
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SCB-2023 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Superiority of SCB-2023 vaccine immune response compared to SCB-2019 for Omicron BA.5 at Day 15, Superiority of SCB-2023 vaccine immune response compared to SCB-2019 for Omicron XBB.1.5 at Day 15 and 2 more. Planned start Aug 2023; status: withdrawn.
02
Drugs
SCB-2023
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05926440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926440.